Ligand Pharmaceuticals (LGND) Interest Expenses (2010 - 2026)

Ligand Pharmaceuticals has reported Interest Expenses for 17 years, with the latest figure at $14.9 million in Q1 2026.

• Quarterly Interest Expenses rose 1618.57% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 163.67% YoY) and the FY2025 annual result came in at $31.7 million, down 55.74% from the prior year.
• Interest Expenses advanced to $14.9 million in Q1 2026 per LGND's latest filing, from $22000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $14.9 million in Q3 2025 and troughed at $1000.0 in Q3 2023.
• A 5-year average of $2.5 million and a median of $741000.0 in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 99.7% in 2023, then soared 74000.0% in 2024.
• Over 5 years, Interest Expenses stood at $240000.0 in 2022, then soared by 363.33% to $1.1 million in 2023, then jumped by 149.55% to $2.8 million in 2024, then plunged by 99.21% to $22000.0 in 2025, then surged by 67627.27% to $14.9 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $14.9 million, $22000.0, and $14.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.